OKYO Pharma Limited(OKYO)

Biotechnology · London, GL

$1.46-0.01 (-0.68%)

Delayed quote: Oct 6, 2026, 3:07 PM EDT

PS Ratio: N/A

Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

The P/S ratio is N/A as of 2026-10-06T19:17:56.303Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:17:56.303Z.

Quote observation: 2026-10-06T19:07:54.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 56,015,925
TTM revenue · period ending 2026-03-31: N/A

FMP input reference: fae3dac89f6aae568c3e1e6131ec6a0b9ed594063ed7dd46d2bf25dadf8b5230

P/E Ratio|Gross Margin|Revenue Growth|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

OKYO PS Ratio Metrics

PS RATIO

N/A

OKYO Competitors' PS Ratio

OKYO

OKYO Pharma Limited

Current

Market Cap

$56.02M

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TLPH

Talphera, Inc.

vs OKYO

Market Cap

$57.09M

PS Ratio

57089.56

TTM Avg

25671.29

3Y Avg

9043.90

5Y Avg

5335.43

BOLD

Boundless Bio, Inc.

vs OKYO

Market Cap

$58.21M

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MDAI

Spectral AI, Inc.

vs OKYO

Market Cap

$53.78M

PS Ratio

3.55

TTM Avg

2.63

3Y Avg

1.90

5Y Avg

4.28

RANI

Rani Therapeutics Holdings, Inc.

vs OKYO

Market Cap

$53.63M

PS Ratio

11.00

TTM Avg

47.77

3Y Avg

38.29

5Y Avg

68.25

INKT

MiNK Therapeutics, Inc.

vs OKYO

Market Cap

$58.54M

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ALDX

Aldeyra The

vs OKYO

Market Cap

$53.30M

PS Ratio

N/A

TTM Avg

4.74

3Y Avg

4.40

5Y Avg

4.40

CNTB

Connect Biopharma Holdings Limited

vs OKYO

Market Cap

$58.75M

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IMA

ImageneBio Inc

vs OKYO

Market Cap

$53.24M

PS Ratio

N/A

TTM Avg

51.20

3Y Avg

31.27

5Y Avg

27.74

ACET

Adicet Bio, Inc.

vs OKYO

Market Cap

$59.17M

PS Ratio

N/A

TTM Avg

16.03

3Y Avg

122.62

5Y Avg

125.37

NAME	MARKET CAP	PS RATIO	TTM	3Y	5Y
OKYO Pharma Limited (OKYO)	$56.02M	N/A	N/A	N/A	N/A
Talphera, Inc. (TLPH)vs ›	$57.09M	57089.56	25671.29	9043.90	5335.43
Boundless Bio, Inc. (BOLD)vs ›	$58.21M	N/A	N/A	N/A	N/A
Spectral AI, Inc. (MDAI)vs ›	$53.78M	3.55	2.63	1.90	4.28
Rani Therapeutics Holdings, Inc. (RANI)vs ›	$53.63M	11.00	47.77	38.29	68.25
MiNK Therapeutics, Inc. (INKT)vs ›	$58.54M	N/A	N/A	N/A	N/A
Aldeyra The (ALDX)vs ›	$53.30M	N/A	4.74	4.40	4.40
Connect Biopharma Holdings Limited (CNTB)vs ›	$58.75M	N/A	N/A	N/A	N/A
ImageneBio Inc (IMA)vs ›	$53.24M	N/A	51.20	31.27	27.74
Adicet Bio, Inc. (ACET)vs ›	$59.17M	N/A	16.03	122.62	125.37

How this was calculated

Half-year reporter: no trailing two-half-year basis, because the half-year figures cannot be checked against the annual report: the newest completed fiscal year's annual revenue and net income are both below 25 million, too small to compare.

The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.

These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.

Sales Valuation

P/S Ratio

N/A

Market Cap / Trailing Twelve-Month Revenue

PS Ratio Formula & Definition

PS Ratio = Market Cap / Revenue (TTM)

The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

PS Ratio: N/A

OKYO PS Ratio Metrics

OKYO Competitors' PS Ratio

Sales Valuation

PS Ratio Formula & Definition

Related Metrics